Literature DB >> 1829730

Locoregional administration of 5-fluoro-2'-deoxyuridine (FdUrd) in Novikoff hepatoma in the rat: effects of dose and infusion time on tumor growth and on FdUrd metabolite levels in tumor tissue as determined by 19F-NMR spectroscopy.

B Naser-Hijazi1, M R Berger, D Schmähl, P Schlag, W E Hull.   

Abstract

The influence of infusion time and dose on the anticancer efficacy of 5-fluoro-2'-deoxyuridine (FdUrd) was investigated using a locoregional therapy model: Novikoff hepatoma transplanted i.m. into the thigh of Wistar rats and FdUrd infusion via a catheter implanted in the femoral artery. In experiment A the FdUrd dose (five daily doses of 12, 19 and 30 mg/kg) and the duration of administration (bolus, 1 h, 5 h, and 24 h) were varied. The change in tumor volume following treatment and the number of rats showing regression vs progression served as indicators of therapy response. The results showed a clear dose dependence, and for each infusion time the 30 mg/kg dose was the most effective, without any signs of general toxicity. At this dose the longest infusion time (24 h) was less effective (regression in three of six rats) compared with 1-h or 5-h treatments (four of five in regression). In experiment B either one or five daily FdUrd doses (15, 30, 60 mg/kg) were administered i.a. for the same infusion times used in experiment A. After treatment, tumors were explanted ex vivo and approximately 1-g tissues samples were immediately frozen in liquid nitrogen for storage. 19F-NMR spectroscopy at 11.7 T was used to quantify FdUrd metabolites [5-fluorouracil (FUra), alpha-fluoro-beta-alanine (F beta Ala), 5-fluorouracil nucleosides and nucleotides (F-Nuc)] in the solid tumor tissue samples (maintained at 4 degrees C) with a detection threshold of about 5 nmol/g. The metabolite signal pattern indicated that FdUrd is first converted to FUra, followed by anabolism primarily to nucleotides in the oxy form (e.g. FUTP). The total amount of fluorine detected in tumor tissue increased with dose and decreased with infusion time. For all treatments FNuc could be detected, even after 24 h infusion, and their levels showed a good linear correlation with the total F. The major catabolite F beta Ala was present in tumor at low levels that correlated poorly with total F, indicating recirculation from other organs (e.g. liver) as the main source. Thus, the NMR method can provide detailed information regarding the efficiency of locoregional treatment (catheter function, drug uptake and metabolism). Initial results of non-invasive in vivo NMR experiments are also presented.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829730     DOI: 10.1007/bf01630711

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  20 in total

1.  Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy.

Authors:  W Semmler; P Bachert-Baumann; F Gückel; F Ermark; P Schlag; W J Lorenz; G van Kaick
Journal:  Radiology       Date:  1990-01       Impact factor: 11.105

2.  Anticancer drugs: studies on experimental liver infusion and additional systemic detoxification.

Authors:  P Friedl; M R Berger; W Rozycki-Gerlach; P Schlag; D Schmähl
Journal:  Cancer Treat Rev       Date:  1987-12       Impact factor: 12.111

3.  Preliminary results of a randomized study of intrahepatic infusion versus systemic infusion of 5-fluoro-2'-deoxyuridine for metastatic colorectal carcinoma.

Authors:  N Kemeny; J Daly
Journal:  Recent Results Cancer Res       Date:  1986

4.  Release of fluoride ion from 5'-deoxy-5-fluorouridine, an antineoplastic fluoropyrimidine, in humans.

Authors:  R Martino; A Lopez; M C Malet-Martino; J Bernadou; J P Armand
Journal:  Drug Metab Dispos       Date:  1985 Jan-Feb       Impact factor: 3.922

Review 5.  Fluorinated pyrimidines and their nucleosides.

Authors:  C Heidelberger; P V Danenberg; R G Moran
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1983

6.  Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits.

Authors:  W Wolf; C A Presant; K L Servis; A el-Tahtawy; M J Albright; P B Barker; R Ring; D Atkinson; R Ong; M King
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

7.  Direct 19F NMR spectroscopic observation of 5-fluorouracil metabolism in the isolated perfused mouse liver model.

Authors:  S Cabanac; M C Malet-Martino; M Bon; R Martino; J F Nedelec; J L Dimicoli
Journal:  NMR Biomed       Date:  1988-06       Impact factor: 4.044

8.  Locoregional application of 5-fluorouracil to the liver: alteration of pharmacokinetics and bone marrow toxicity in rats with thioacetamide-induced cirrhosis.

Authors:  J L Aguiar; M R Berger; N Frank
Journal:  Toxicol Lett       Date:  1987-04       Impact factor: 4.372

9.  Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.

Authors:  W E Hull; R E Port; R Herrmann; B Britsch; W Kunz
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701

10.  Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo.

Authors:  P M McSheehy; M J Prior; J R Griffiths
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

View more
  6 in total

1.  Intraarterial hepatic chemotherapy with fluorouracil, fluorodeoxyuridine, mitomycin C, cisplatin or methotrexate as single-agent anticancer drugs for a transplanted experimental liver tumor in rats.

Authors:  S Kurth; D Bulian; B Kreft; T Riemenschneider
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure.

Authors:  Hanneke W M van Laarhoven; Giulio Gambarota; Jasper Lok; Martin Lammens; Yvonne L M Kamm; Theo Wagener; Cornelis J A Punt; Albert J van der Kogel; Arend Heerschap
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

3.  Non-invasive molecular and functional imaging of cytosine deaminase and uracil phosphoribosyltransferase fused with red fluorescence protein.

Authors:  Ligang Xing; Xuelong Deng; Khushali Kotedia; Ellen Ackerstaff; Vladimir Ponomarev; C Clifton Ling; Jason A Koutcher; Gloria C Li
Journal:  Acta Oncol       Date:  2008       Impact factor: 4.089

4.  Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.

Authors:  M Barberi-Heyob; B Weber; J L Merlin; C Dittrich; E A de Bruijn; E Luporsi; F Guillemin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  The future of NMR metabolomics in cancer therapy: towards personalizing treatment and developing targeted drugs?

Authors:  Marie S A Palmnas; Hans J Vogel
Journal:  Metabolites       Date:  2013-05-17

6.  Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma.

Authors:  Y J L Kamm; G J Peters; W E Hull; C J A Punt; A Heerschap
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.